ArticleNature communications2019
Targets of complement-fixing antibodies in protective immunity against malaria in children.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 98 citations in OpenAlex.
- Declining Antibody Affinity Over Time After Human Vaccination With a Plasmodium falciparum Merozoite Vaccine Candidate.The Journal of infectious diseases · 2024Trial
- Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial.The Journal of infectious diseases · 2021Trial
- Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives.The Journal of infectious diseases · 2019Trial
- An abundant merozoite surface protein ofeLife · 2026Article
- Antibody Responses to the ConservedPathogens (Basel, Switzerland) · 2026Article
- The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies.Disease models & mechanisms · 2026Article
- Cellular and molecular interactions underlying the peripheral immune responses to blood-stage malaria infections.ImmunoHorizons · 2026Review
- A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria.Immunity · 2026Article
- Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials.Frontiers in immunology · 2026Article
- Targeting a malaria merozoite surface protein with mRNA vaccine generates multifunctional antibodies.Frontiers in immunology · 2026Article
- The N-terminal region of malaria vaccine candidatebioRxiv : the preprint server for biology · 2025Article
- Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial.EClinicalMedicine · 2025Article
- FcγR binding differentially contributes to protection by two human monoclonal antibodies targetingScience translational medicine · 2025Article
- Deposition of complement regulators on the surface of Plasmodium falciparum merozoites depends on the immune status of the host.PLoS pathogens · 2025Article
- Article
- The impact of Plasmodium-driven immunoregulatory networks on immunity to malaria.Nature reviews. Immunology · 2024Review
- Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.Life science alliance · 2024Article
- Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.Immunity · 2024Article
- How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays.Vaccines · 2024Review
- PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.NPJ vaccines · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 5 countries.
Funding
Abstract
Antibodies against P. falciparum merozoites fix complement to inhibit blood-stage replication in naturally-acquired and vaccine-induced immunity; however, specific targets of these functional antibodies and their importance in protective immunity are unknown. Among malaria-exposed individuals, we show that complement-fixing antibodies to merozoites are more strongly correlated with protective immunity than antibodies that inhibit growth quantified using the current reference assay for merozoite vaccine evaluation. We identify merozoite targets of complement-fixing antibodies and identify antigen-specific complement-fixing antibodies that are strongly associated with protection from malaria in a longitudinal study of children. Using statistical modelling, combining three different antigens targeted by complement-fixing antibodies could increase the potential protective effect to over 95%, and we identify antigens that were common in the most protective combinations. Our findings support antibody-complement interactions against merozoite antigens as important anti-malaria immune mechanisms, and identify specific merozoite antigens for further evaluation as vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.